论文部分内容阅读
在香港举行的“中国药品管理与香港医药发展研讨会”上,国家药品监督管理局局长郑筱萸应邀发表了专题演讲。他指出,虽然中药近年来取得长足发展,但存在三个缺乏:①缺乏高技术含量的创新中药;②缺乏中药质量标准的可控性机制;③缺乏国际认可的「大品种」。我国现时虽是一个制药大国,化学药品年产量居全球第二位,出口量居全球首位,但中药在国际医药市场
At the “China Pharmaceutical Management and Hong Kong Pharmaceutical Development Seminar” held in Hong Kong, the Director of the State Drug Administration Zheng Zhen was invited to deliver a keynote speech. He pointed out that although Chinese medicine has achieved rapid development in recent years, there are three shortages: 1 lack of high-tech innovative Chinese medicine; 2 lack of controllability of Chinese medicine quality standards; 3 lack of internationally recognized “big breeds.” Although China is currently a big pharmaceutical country, its annual output of chemical drugs ranks second in the world, and its export volume ranks first in the world, but Chinese medicine is in the international pharmaceutical market.